ReviewJMA journal2025
Development of the World's First In Vitro Cancer Epigenome Diagnostic through Biomarker Research for Personalized Cancer Treatment of RAS-wild-type Colorectal Cancer -Secondary Publication - Secondary Publication.
Review in JMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigenetic regulation mechanisms such as deoxy ribonucleic acid (DNA) methylation are important for controlling various biological phenomena by regulating gene expression at the genome level. Epigenetic abnormalities are associated with the onset of diseases including cancers. Aberrant DNA methylation is an important epigenetic change in the development and progression of colorectal cancer. DNA methylation in tumor tissues occurs mainly in CpG islands in the promoter regions of genes and inactivates gene functions by negatively suppressing transcription. The CpG island methylator phenotype (CIMP) is an important carcinogenic mechanism in colorectal cancer related to DNA methylation and is involved in approximately 20% of all colorectal cancers. However, CIMP does not always represent the genome-wide DNA methylation status in colorectal cancer. We developed a new method to assess genome-wide DNA methylation status and showed that it is a predictor of the efficacy of anti-estimated glomerular filtration rate (EGFR) antibody drugs and a prognostic factor. This new method has received regulatory approval as a new in vitro diagnostic for predicting sensitivity to anti-EGFR antibody drugs in colorectal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.